• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Niagen Bioscience Inc.

    4/29/26 4:05:33 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $NAGE alert in real time by email
    DEFA14A 1 nagedefa14a2026proxynotice.htm DEFA14A NAGE DEFA 14A 2026 Proxy Notice

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 14A
    Proxy Statement Pursuant to Section 14(a) of the
    Securities Exchange Act of 1934 (Amendment No.   )
    Filed by the Registrant  ☑
    Filed by a party other than the Registrant  ☐
    Check the appropriate box:
    ☐Preliminary Proxy Statement
    ☐Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐Definitive Proxy Statement
    ☑Definitive Additional Materials
    ☐Soliciting Material under §240.14a-12
    NIAGEN BIOSCIENCE, INC.
    (Name of Registrant as Specified In Its Charter)
     
    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)
    Payment of Filing Fee (Check all boxes that apply):
    ☑No fee required.
    ☐Fee paid previously with preliminary materials
    ☐Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
     
    www.investorvote.com/NAGE Step 1: Go to www.investorvote.com/NAGE. Step 2: Click on the icon on the right to view meeting materials. Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in. Online Go to www.investorvote.com/NAGE or scan the QR code — login details are located in the shaded bar below. Shareholder Meeting Notice 049TYA Important Notice Regarding the Availability of Proxy Materials for the Niagen Bioscience, Inc. Annual Shareholder Meeting to be Held on June 24, 2026 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual shareholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The 2025 Annual Report and Proxy Statement are available at www.Niagenbioscience.com, Investor Relations Section and: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before June 14, 2026 to facilitate timely delivery. 2 N O T Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares. Votes submitted electronically must be received by 11:59 pm, ET on June 23, 2026. MMMMMMMMMMMM M M M M M M M M M 0 0 0 0 0 1 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 ADD 5 ADD 6 ENDORSEMENT_LINE______________ SACKPACK_____________ 1234 5678 9012 345 C 1234567890 C O Y MMMMMMM


     
    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. —  Internet – Go to www.investorvote.com/NAGE. —  Phone – Call us free of charge at 1-866-641-4276. —  Email – Send an email to investorvote@computershare.com with “Proxy Materials Niagen Bioscience, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, all requests for a paper copy of proxy materials must be received by June 14, 2026. Niagen Bioscience, Inc.’s Annual Meeting of Shareholders will be held on Wednesday, June 24, 2026 at 3:00 pm PT. The meeting will be held at 10900 Wilshire Blvd. Suite 600, Los Angeles, CA 90024. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommend a vote FOR all the nominees listed and FOR Proposals 2 and 3. 1. Election of Directors: 01 - Frank Jaksch, Jr. 02 - Robert Fried 03 - Steven Rubin 04 - Wendy Yu 05 - Gary Ng 06 - Kristin Patrick 07 - Ann Cohen 08 - Hamed Shahbazi 2.  Ratification of the Audit Committee’s selection of Crowe LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 3.  A nonbinding advisory vote of the Company’s stockholders, as recommended by the Compensation Committee and approved by the Board, on the compensation of the Company’s named executive officers disclosed in the Proxy Solicitation Materials PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. Shareholder Meeting Notice


     
     
    Get the next $NAGE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NAGE

    DatePrice TargetRatingAnalyst
    5/27/2025$13.00Buy
    Canaccord Genuity
    More analyst ratings

    $NAGE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity initiated coverage on Niagen Bioscience with a new price target

    Canaccord Genuity initiated coverage of Niagen Bioscience with a rating of Buy and set a new price target of $13.00

    5/27/25 9:10:59 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Fried Robert N exercised 20,000 shares at a strike of $2.61, increasing direct ownership by 2% to 1,058,981 units (SEC Form 4)

    4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

    4/27/26 8:33:59 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by SVP, General Counsel Lopez Carlos Luis

    4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

    2/24/26 4:47:28 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 4 filed by Chief Financial Officer Pamir Ozan

    4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

    2/24/26 4:46:19 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    SEC Filings

    View All

    Niagen Bioscience Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Niagen Bioscience, Inc. (0001386570) (Filer)

    5/6/26 4:01:25 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 10-Q filed by Niagen Bioscience Inc.

    10-Q - Niagen Bioscience, Inc. (0001386570) (Filer)

    5/6/26 4:01:00 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form DEFA14A filed by Niagen Bioscience Inc.

    DEFA14A - Niagen Bioscience, Inc. (0001386570) (Filer)

    4/29/26 4:05:33 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Niagen Bioscience to Present at the 16th Annual East Coast IDEAS Investor Conference

    Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior management will present at the East Coast IDEAS Investor Conference on Thursday, June 11, 2026, at The Westin Times Square in New York, NY. IDEAS Conferences provide independent regional venues for quality companies to present their investment merits to influential audiences of investment professionals, offering investor-sponsored events designed to benefit regional investment communities. Niagen Bioscience CEO, Rob Fried, will present on Thursday, June 11, from 2:40 - 3:15 PM ET in the Presenting Room. The pres

    6/3/26 8:34:00 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    Niagen Bioscience Renames ChromaDex External Research Program to the Niagen Research Program, Strengthening Position as the Global Leader in NAD+ Science

    The program has supported more than 300 research collaborations across leading institutions worldwide, contributing to over 45 published human clinical studies on Niagen® and advancing understanding of NAD+ biology beyond blood biomarkers into clinically relevant tissues and systems Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the official renaming of the ChromaDex External Research Program (CERP) to the Niagen Research Program, reflecting the Company's name evolution with a focus on advancing the understanding and applications of NAD+ through its flagship ingredient, N

    6/2/26 8:32:00 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    Niagen Bioscience Announces Participation in Upcoming Investor Conferences

    Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that senior leadership will participate in the following upcoming conferences: 31st Annual Sohn Investment Conference Location: Jazz at Lincoln Center's Frederick P. Rose Hall Date: May 12, 2026 Format: Emerging Company Pavilion, a curated showcase of 8-10 select companies Management: Ozan Pamir, CFO 4th Annual Benchmark Consumer One-On-One Conference Location: New York Athletic Club Date: May 19, 2026 Format: One-on-one meetings Management: Rob Fried, CEO, and Ozan Pamir, CFO If you would like t

    5/8/26 8:32:00 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Pamir Ozan bought $45,616 worth of shares (6,685 units at $6.82), increasing direct ownership by 154% to 7,372 units (SEC Form 4)

    4 - Niagen Bioscience, Inc. (0001386570) (Issuer)

    11/17/25 8:23:28 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    Leadership Updates

    Live Leadership Updates

    View All

    Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board

    Appointment of renowned gerontologist and mitochondrial biology expert underscores Niagen Bioscience's commitment to advancing cutting-edge NAD+ and healthspan research Niagen Bioscience, Inc. (NASDAQ:NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, is pleased to announce the appointment of Dr. Pinchas Cohen to its Scientific Advisory Board (SAB).​ Dr. Cohen is an internationally recognized leading expert in healthy aging and mitochondrial biology. He serves as Dean of the University of Southern California (USC) Leonard Davis School of Gerontology and is a Distinguished Professor of Gerontology

    4/29/25 8:32:00 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    $NAGE
    Financials

    Live finance-specific insights

    View All

    Niagen Bioscience, Inc. Reports First Quarter 2026 Financial Results

    Net sales increased to $31.5 million Gross margin improved to 63.5% Net income of $6.3 million, up $1.3 million from the prior year and adjusted EBITDA of $3.8 million Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced financial results for the first quarter of 2026. First Quarter 2026 Financial Highlights Total net sales increased 3% to $31.5 million, including $22.4 million from Tru Niagen®. Excluding the recently sold Analytical Reference Standards and Services segment from both periods, net sales rose 5% to $31.1 million. Gross margin of 63.5%, reflecting continued strength in business mix. Net income of $6.3 million, including a $4.8 million gain on the divestiture

    5/6/26 4:02:00 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    Niagen Bioscience to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

    Niagen Bioscience, Inc. (NASDAQ:NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that it will hold a conference call on Wednesday, May 6, 2026, at 4:30 p.m. ET to discuss its financial results for the first quarter, which ended March 31, 2026. The financial results will be reported in a press release after the close of regular stock market trading hours on Wednesday, May 6, 2026. Investor Conference Call: A live webcast will be held on Wednesday, May 6, 2026, at 4:30 p.m. Eastern Daylight Time (1:30 p.m. Pacific Daylight Time) to discuss Niagen Bioscience's first quarter financial results and provide a

    4/22/26 8:32:00 AM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care

    Niagen Bioscience Reports 30% Year-Over-Year Net Sales Increase to $129.4 million, 103% Net Income Increase to $17.4 million or $0.22 Basic EPS in 2025

    Net sales increased 30% year-over-year to $129.4 million in 2025 Gross margin increased 250 bps year-over-year to 64.3% in 2025 Net income increased 103% year-over-year to $17.4 million in 2025 Adjusted EBITDA increased 139% year-over-year to $20.4 million in 2025 Cash and cash equivalents totaled $64.8 million at December 31, 2025 compared to $44.7 million at December 31, 2024 Full year 2026 net sales outlook reflects between 10-15% growth, excluding the recently sold reference standards segment Niagen Bioscience, Inc. (NASDAQ:NAGE) today announced its fourth quarter and fiscal year 2025 financial results. Fourth Quarter 2025 Financial Highlights Compared to Prior Year Quarter Total

    3/4/26 4:02:00 PM ET
    $NAGE
    Medicinal Chemicals and Botanical Products
    Health Care